FTSE Earnings Week: What AstraZeneca and GSK's Results Mean for Your Pension

Five of the FTSE 100's biggest names report results this week — AstraZeneca, GSK, Unilever, Barclays and Rolls-Royce — giving investors, and anyone with money in a UK pension or tracker fund, their clearest read yet on how the blue-chip index is holding up in 2026.

What's being reported

AstraZeneca kicked off the week on Monday with half-year results showing revenue up 6% at constant exchange rates to $30.7 billion, slightly ahead of market expectations. Attention is also on the company's drug pipeline after July's setback in the Phase 3 trial for Wainua, one of its key experimental treatments.

GSK follows on Tuesday amid reports the pharma group faces a £3.6 billion sales shortfall against prior targets. Investors want clarity on whether newly-acquired Nuvalent assets, alongside its existing oncology, HIV and respiratory portfolio, can offset the abandoned camlipixant programme.

Unilever, Barclays and Rolls-Royce round out the week's headline reporters, spanning consumer goods, banking and aerospace — a reasonably representative cross-section of the wider FTSE 100.

Why this matters if you don't actively trade shares

If you hold a workplace pension, a Stocks and Shares ISA tracking a UK index, or a default pension fund, you very likely own a slice of most of these companies without realising it — AstraZeneca and GSK alone represent a meaningful chunk of the FTSE 100 by market value. Half-year results season is one of the few points in the year where the underlying health of these businesses becomes visible all at once, rather than trickling out gradually.

A weak set of results across several large-caps in the same week can drag down index-level returns even if your personal portfolio feels untouched, simply because of how heavily most UK trackers are weighted toward a handful of large companies.

What to actually do

• Resist reacting to single-day share price moves in a pension you're not due to draw from for years — short-term earnings reactions rarely predict long-term returns.
• If you hold individual shares in any of this week's reporters, read the results summary rather than just the headline share price move.
• Check how concentrated your pension or ISA fund is in UK equities versus global markets — the FCA's guidance on investment risk is a good starting point if you're unsure.
• Use earnings season as a prompt to review your overall asset allocation once a year, rather than adjusting holdings reactively to news.

Key Numbers

• 6% — AstraZeneca's H1 2026 constant-currency revenue growth, to $30.7 billion
• £3.6 billion — reported sales shortfall facing GSK against prior targets
• 5 — major FTSE 100 companies reporting results this week

Sources

• AskTraders: UK Earnings Week — FTSE's AstraZeneca, GSK, Unilever, Barclays and Rolls-Royce Take Centre Stage
• Yahoo Finance: FTSE 100 held back by AstraZeneca trial setback
• Invezz: FTSE 100 shares to watch — Lloyds, Barclays, IAG, NatWest, GSK, AstraZeneca
• Hargreaves Lansdown: Next week on the stock market

Educational content only — not financial advice.